Cartesian Therapeutics, Inc. (RNAC) Financial Statements (2025 and earlier)

Company Profile

Business Address 7495 NEW HORIZON WAY
FREDERICK, MD 21703
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments76,911134,602128,055138,68589,89337,403
Cash and cash equivalent76,911106,438114,057138,68589,89337,403
Short-term investments  28,16413,998   
Restricted cash and investments  289  279 
Receivables5,8706,5969,9147,2245,000 
Contract with customer, asset, after allowance for credit loss 2,9813,162    
Other undisclosed current assets4,9673,4896,4745,4341,4954,673
Total current assets:90,729148,138144,443151,34396,66742,076
Noncurrent Assets
Operating lease, right-of-use asset10,06811,6179,82910,948301
Property, plant and equipment2,1132,7942,1421,3951,2222,127
Intangible assets, net (including goodwill)198,763     
Goodwill48,163     
Intangible assets, net (excluding goodwill)150,600     
Restricted cash and investments1,3771,3111,3791,3791,379279
Other noncurrent assets      
Other undisclosed noncurrent assets2,0002,0262,090370  
Total noncurrent assets:214,32117,74815,44014,0922,9022,406
TOTAL ASSETS:305,050165,886159,883165,43599,56944,482
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,88314,40011,3588,58913,99212,800
Taxes payable601   
Accounts payable3,1503162244435001,100
Accrued liabilities14,73314,08410,5338,14613,49211,700
Deferred revenue 2,31159353,88372,0501,674
Debt  8,4765,961 19,27721,385
Derivative instruments and hedges, liabilities 28,307     
Contract with customer, liability959
Other undisclosed current liabilities19,7081,6081,049908  
Total current liabilities:68,20925,07772,25181,54734,94335,144
Noncurrent Liabilities
Long-term debt and lease obligation  17,78628,27134,440  
Long-term debt, excluding current maturities  17,78619,67324,793  
Liabilities, other than long-term debt28,18010,05511,41738,74614,68014,756
Deferred revenue 3,538 11,41738,74614,680
Contract with customer, liability13,818
Deferred rent credit      34
Deferred income tax liabilities15,853    
Other liabilities      904
Operating lease, liability8,78910,0558,5989,647 
Other undisclosed noncurrent liabilities348,29119,14025,42328,70841,549 
Total noncurrent liabilities:376,47146,98165,111101,89456,22914,756
Total liabilities:444,68072,058137,362183,44191,17249,900
Temporary equity, including noncontrolling interest 296,851     
Equity
Equity, attributable to parent(440,184)93,82822,521(18,006)8,397(5,418)
Common stock1615121193
Additional paid in capital179,047493,308457,391391,175348,664279,539
Accumulated other comprehensive loss(4,600)(4,558)(4,566)(4,563)(4,523)(4,557)
Accumulated deficit(614,647)(394,937)(430,316)(404,629)(335,753)(280,403)
Other undisclosed equity 3,703     
Total equity:(436,481)93,82822,521(18,006)8,397(5,418)
TOTAL LIABILITIES AND EQUITY:305,050165,886159,883165,43599,56944,482

Income Statement (P&L) ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues26,004110,77785,07716,5976,677903
Gross profit:26,004110,77785,07716,5976,677903
Operating expenses(112,420)(96,239)(89,674)(73,418)(59,132)(65,925)
Operating income (loss):(86,416)14,538(4,597)(56,821)(52,455)(65,022)
Nonoperating income (expense)(143,907)2,38159405(519)1,180
Investment income, nonoperating(144,636)2,073442608341,050
Other nonoperating income (expense)6913301589(1,306)10
Interest and debt expense (2,833)(3,031)(2,844)(2,017)(1,519)(1,494)
Income (loss) from continuing operations before equity method investments, income taxes:(233,156)13,888(7,382)(58,433)(54,493)(65,336)
Other undisclosed income (loss) from continuing operations before income taxes(5,554)20,882(2,339)   
Income (loss) from continuing operations before income taxes:(238,710)34,770(9,721)(58,433)(54,493)(65,336)
Income tax expense (benefit)19,000609(15,966)   
Income (loss) from continuing operations:(219,710)35,379(25,687)(58,433)(54,493)(65,336)
Loss before gain (loss) on sale of properties:(25,687)(58,433)(54,493)(65,336)
Net income (loss):(219,710)35,379(25,687)(58,433)(54,493)(65,336)
Other undisclosed net loss attributable to parent    (10,443)(857) 
Net income (loss) attributable to parent:(219,710)35,379(25,687)(68,876)(55,350)(65,336)
Other undisclosed net loss available to common stockholders, basic (37,550)     
Net income (loss) available to common stockholders, basic:(257,260)35,379(25,687)(68,876)(55,350)(65,336)
Dilutive securities, effect on basic earnings per share      
Net income (loss) available to common stockholders, diluted:(257,260)35,379(25,687)(68,876)(55,350)(65,336)

Comprehensive Income ($ in thousands)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(219,710)35,379(25,687)(58,433)(54,493)(65,336)
Other comprehensive loss      (137)
Comprehensive income (loss):(219,710)35,379(25,687)(58,433)(54,493)(65,473)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(42)8(3)(10,483)(823) 
Comprehensive income (loss), net of tax, attributable to parent:(219,752)35,387(25,690)(68,916)(55,316)(65,473)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: